Sol-Gel Technologies Announces Collaborative Agreement With Perrigo
Sol-Gel Technologies Ltd. recently announced it has entered into a collaborative agreement with Perrigo Israel, an affiliate of Perrigo Company plc, for the development, manufacturing, and commercialization of a generic product candidate.
Under the terms of the agreement, Perrigo will conduct the regulatory, scientific, clinical, and technical activities necessary to develop the generic product candidate and seek regulatory approval with the US FDA. If approved by the FDA, Perrigo has agreed to commercialize the generic product candidate in the US. Sol-Gel and Perrigo will share the development costs and the gross profits generated from the sales of the generic product candidate, if approved.
“The expansion of our generic product agreement with Perrigo is another important step in advancing our generic business. Our generic business includes ivermectin cream, 1%, sponsored by Perrigo, for which we have the FDA’s tentative approval as of January 29, 2018, and five generic drug candidates, three of which are being developed with Perrigo and one being developed with Douglas Pharmaceuticals,” said Dr. Alon Seri-Levy, Chief Executive Officer of Sol-Gel.
Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is the world’s largest manufacturer of over-the-counter (“OTC”) healthcare products and supplier of infant formulas for the store brand market. The Company also is a leading provider of branded OTC products throughout Europe, as well as a leading producer of “extended topical” prescription drugs. Perrigo, headquartered in Ireland, sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China. For moreinformation, visit (http://www.perrigo.com).
Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel’s current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. For more information, visit www.sol-gel.com.
Total Page Views: 64